Abeona Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ABEO research report →
Range $15 – $21
Price Chart
About the company
Abeona Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, focused on creating innovative gene and cell therapies to address severe and uncommon genetic diseases. Its leading program, EB-101, an autologous gene-corrected cell therapy, is presently in a Phase III clinical trial for treating recessive dystrophic epidermolysis bullosa.
- CEO
- Vishwas Seshadri
- IPO
- 1980
- Employees
- 226
- HQ
- Cleveland, OH, US
Get TickerSpark's AI analysis on ABEO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $138.30M
- P/E
- -2.16
- Fwd P/E
- 15.13
- PEG
- 0.01
- P/S
- 3.55
- P/B
- 1.11
- EV/EBITDA
- -1.58
- Div Yield
- 0.00%
- Gross Margin
- 58.24%
- Op Margin
- -186.10%
- Net Margin
- -160.30%
- ROE
- -44.82%
- ROIC
- -45.99%
Latest fiscal year · YoY change
- Revenue
- $5.82M+0.0%
- Gross Profit
- $4.29M+247.5%
- Op Income
- $-89,448,000
- Net Income
- $71.18M+211.7%
- EPS
- $1.34+186.5%
- OCF Growth
- -36.3%
- FCF Growth
- -44.2%
- 52W High
- $7.65
- 52W Low
- $2.09
- 50D MA
- $4.38
- 200D MA
- $5.33
- Beta
- 1.30
- RSI (14)
- 27
- Avg Volume
- 1.66M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Abeona delivered continued ZEVASKYN launch progress in Q3 and added a Phase III-ready EoE asset, while emphasizing that manufacturing timing and revenue recognition remain variable through year-end.· November 9, 2026
- ZEVASKYN net revenue was $13.5 million, up 18% from $11.4 million in Q2, with 6 patients treated in the quarter and 15 treated since launch.
- Two more qualified treatment centers were activated, bringing the network to 8 sites, and 4 centers have now treated patients firsthand.
- Management said treatment timing will stay variable through year-end and into early 2027 because of scheduling, payer steps, and a planned manufacturing shutdown.
- Abeona acquired ABO-801 for EoE, citing >$750 million peak annual revenue potential and planning a Phase III study around mid-2027.
- Cash was $134.9 million at quarter-end before the planned $30 million private placement proceeds were included.
Abeona reported third-quarter net ZEVASKYN revenue of $13.5 million, up 18% from $11.4 million in the second quarter. Cost of sales was $5.7 million versus $4.2 million in Q2, R&D was $3.7 million versus $5.0 million, and SG&A was $17.1 million versus $15.8 million. Net loss was $4.8 million, or $0.08 per basic and diluted share, compared with a net loss of $20.2 million, or $0.35 per share, in Q2. The company ended Q3 with $134.9 million in cash, cash equivalents and short-term investments, down from $146.8 million at June 30. For the ZEVASKYN launch, management said 6 patients were treated in the quarter, 5 of those treatments were recognized as revenue, and 1 was not recognized because the batch was out of specification for the pan-CK identity assay. Forward-looking, management expects treatment timing to remain variable through year-end and into early 2027, and said biopsies will stop around mid-November and resume in mid-January. For ABO-801, the company plans a ~400-patient Phase III study, to discuss the design with FDA at a Type C meeting, initiate in mid-2027, and report results around end of 2028. Management said clinical development cost to get ABO-801 to FDA approval is about $50 million to $60 million.
The CEO framed the quarter as a turning point: Abeona is still focused on building ZEVASKYN as the commercial base, but is also broadening the company with ABO-801 to create a more diversified, durable business. He stressed that ABO-801 fits Abeona’s experience in late-stage development and regulatory execution, and said the company can advance it without distracting the ZEVASKYN launch team. His tone was constructive and opportunistic, but disciplined, repeatedly emphasizing focus, phased execution, and capital allocation.
The CFO highlighted the financial bridge from launch to scale: Q3 ZEVASKYN revenue was $13.5 million, cost of sales was $5.7 million, and the company posted a net loss of $4.8 million, or $0.08 per share. He said the company ended the quarter with $134.9 million in cash, cash equivalents and short-term investments, not including the expected $30 million private placement proceeds. On ABO-801, he outlined the transaction terms: $20 million of Abeona stock issued at closing, plus $30 million upon FDA approval, up to $30 million in commercial milestones, and tiered royalties in the low to mid-teens. He also said the clinical development cost for ABO-801 to FDA approval is about $50 million to $60 million and that gross margins should improve materially as manufacturing utilization rises, with a long-run target of about 85% to 90% at full capacity.
Analysts focused on three areas: ZEVASKYN patient flow, manufacturing reliability, and the ABO-801 strategy. Management said it will not quantify the funnel mid-quarter, but there are patients at all 8 QTCs, some already in prior authorization or financial clearance, and one out-of-spec batch occurred out of 15 treated patients. On manufacturing, management said it is working with FDA on process, assay, and quality-control improvements and expects capacity to reach 6 patients per month now, potentially 10 manufacturing slots per month within existing clean-room space by mid-2027. For ABO-801, management said the next Phase III could plausibly be a single trial, but that will be confirmed after a Type C meeting with FDA; the design will switch from PROSE to DSQ, use a 12-week primary readout, include a 24-week durability endpoint, and enroll more moderate/severe patients. Management also said ABO-801 will be positioned as a step before biologics, though prior DUPIXENT patients may still be included after washout.
The positive case from the call is that ZEVASKYN appears to be building real commercial infrastructure: more centers are activated, first-time treatment experience is expanding, and management believes payer coverage and reimbursement support are already in place across most commercial lives. Abeona also argued that ABO-801 has unusually rich Phase III history and a differentiated oral profile, which could create a second growth driver without derailing the launch. Management’s confidence on long-term margin expansion and added manufacturing capacity further supports the idea that scale could improve the economics meaningfully.
The main risks discussed were launch timing and operational variability: treatments can slip because of payer steps, scheduling, and manufacturing shutdowns, and management explicitly said some patients may move into early 2027. There was also a quality/release issue on one batch, showing that revenue recognition can be affected by out-of-spec manufacturing even when management says clinical safety and efficacy are not compromised. On ABO-801, the asset still needs FDA alignment on study design, the planned trial won’t start until mid-2027, and the company is still dependent on future execution before the program can contribute commercially.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 53.7%
- Shares Outstanding
- 57.15M
- Float Shares
- 30.70M
of shares held by institutions
2 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| B. Riley Wealth Management, Inc. | 12.90K | ▲ 12.90K |
Held by 122 ETFs
Biggest fund positions in ABEO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 13, 26 | Charles Faith L. | buy | 15,000 |
| Sep 29, 26 | Seshadri Vishwas | sell | 19,608 |
| Sep 29, 26 | Vazzano Joseph Walter | sell | 9,191 |
| Sep 29, 26 | O'Malley Brendan M. | sell | 6,727 |
| Sep 29, 26 | Vasanthavada Madhav | sell | 4,902 |
| Sep 1, 26 | Alvino Mark | sell | 15,000 |
| Jul 21, 26 | Vazzano Joseph Walter | sell | 1,478 |
| Jul 9, 26 | Vazzano Joseph Walter | sell | 24,880 |
| Jul 9, 26 | Seshadri Vishwas | sell | 67,971 |
| Jul 9, 26 | O'Malley Brendan M. | sell | 12,050 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ABEO coverage
Recent articles, reports, and earnings notes.
No research on ABEO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ABEO report →Abeona Therapeutics Sees ZEVASKYN Treatments Picking Up in 2027 as Centers Ramp Up
marketbeat.com · Nov 22
Abeona Therapeutics Plans New Phase 3 Trial for ABO-801 as ZEVASKYN Launch Expands
marketbeat.com · Nov 12
Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
globenewswire.com · Nov 10
Abeona Therapeutics Inc. (ABEO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 9
What Abeona Therapeutics (ABEO) Said on Its Q3 Earnings Call
marketbeat.com · Nov 9
Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
globenewswire.com · Nov 9
Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement
globenewswire.com · Nov 9
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.